Kornimate/medical-research-clean huggingface dataset:
furosemide stress test to predict need of renal replacement therapy in ischemic acute tubular necrosis in icu

Conditions: Acute Kidney Injury

Summary: ischemic acute tubular necrosis (atn) is one of the main cause of acute kidney injury (aki) in intensive care units (icu). sepsis and cardio-pulmonary bypass (cpb) are major providers. there is no validated tool to predict the evolution of aki is icu. furosemide stress test (fst) may predict evolution of atn-related aki outside icu in terms of progressive aki, need for renal replacement therapy (rrt) or inpatient mortality with improved performance comparing to biomarkers. fst has not been validated in a prospective cohort in icu in the settings of ischemic atn. further aim to determine whether fst would be a useful tool to identify patients with slight to moderate aki (kdigo stage 1 and 2) who will evolve towards need for rrt following akiki (the artificial kidney initiation in kidney injury ) delayed initiation criteria.

further will enroll consecutive patients with aki kdigo stage 1 or 2 associated with a sepsis or following a cardiac surgery with cpb within 72h. patients must have achieved a hemodynamic stabilization confirmed by clinical (no need for intravenous fluids, no significant variation of noradrenaline) and non-clinical (trans-thoracic echocardiography, passive leg rise or other validated tool) assessment. included patients will receive 1 to 1.5 mg/kg of furosemide. urine output will be measured for 6 hours and compensated by the same volume of intravenous crystalloids. need for rrt will be assess at 2-hour, 6-hour and daily up to day 7, following the akiki-study delayed initiation arm criteria. further aim to evaluate fst in a well-defined prospective cohort of ischemic atn-related aki as predictor of need for rrt within a week.

Eligibility criteria:
inclusion criteria: * age over 18 years old * hospitalized in icu at day of inclusion * diagnosis of sepsis defined as proven or suspected infection and increase of the sofa (sequential organ failure assessment) score by 2 points or more compared to basal or cardiothoracic surgery with cbp (cardiopulmonary bypass) within 72 hours before inclusion * adequate cardiac output and volemia assessed by cardiac ultrasound, venous saturation in oxygen (scvo2) or δpp * hemodynamic stabilization : stable norepinephrine dosage (or \<20% variations) with no vascular filling during the last 3 hours * aki stage i or ii in kdigo classification exclusion criteria: * chronic kidney disease with glomerular filtration rate ≤ 30 ml/mn/1,73m2 * obstructive aki * aki stage iii in kdigo classification * known allergy to loop diuretics * contraindications to furosemide * fst not feasible within 12 hours of eligibility * previous aki during the same hospitalization * pregnancy or breastfeeding women * subject under a legal protective measure * no affiliation to a social regime or cmu

Keywords: ischemic acute kidney injury intensive care units aki icu fst furosemide stress test rrt renal replacement therapy sepsis cardio-pulmonary bypass
t-vec in non-melanoma skin cancer

Conditions: Non-melanoma Skin Cancer; Basal Cell Carcinoma; Squamous Cell Carcinoma; Cutaneous Lymphoma; Merkel Cell Carcinoma

Summary: evaluation of the mechanism of action of talimogene laherparepvec (t-vec) in patients with locally advanced non-melanoma skin cancer.

this study evaluates the administration of t-vec in non-melanoma skin cancer. the aim is to evaluate the effectiveness, safety and tolerability of t-vec in patients with non-melanoma skin cancer through determination of local immune effects after repeated t-vec injections.

Eligibility criteria:
inclusion criteria: * subjects age ≥ 18 years * histologically confirmed diagnosis of locally advanced squamous cell carcinoma, basal cell, carcinoma, merkel cell carcinoma or cutaneous t cell lymphoma * at least 1 injectable cutaneous lesion ≥ 20 mm in longest diameter or multiple injectable lesions that in aggregate have a longest diameter of ≥ 50 mm * eastern cooperative oncology group-status (ecog status) 0 or 1 * adequate organ functions exclusion criteria: * hypersensitivity to t-vec or any of ist components * presence of organ and lymph node metastases * history or evidence of active autoimmune disease that requires systemic treatment * evidence of clinically significant immunosuppression * active herpetic skin lesions or prior complications hereof * pregnancy, breast feeding * requires intermittent or chronic systemic treatment with an antiherpetic drug * acute or chronic active hepatitis b or c infection or hiv infection
68ga-dotatate neuroblastoma imaging pilot

Conditions: Neuroblastoma

Summary: neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. staging of the disease can be done by different imaging strategies (ct, mri, scintigraphy and pet/ct). discrepancies may be observed among these different strategies resulting in different treatment strategies. the goal of this study is to assess the feasibility and safety of 68ga-dotatate and to compare it to 123i-mibg when investigating neuroblastoma.

background: neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. initial staging of the disease and monitoring of the treatment response can be performed with different imaging modalities that include contrast-enhanced computed tomography (cect), ultrasound, magnetic resonance imaging (mri), bone scintigraphy and 123i-mibg scintigraphy. another potential target for neuroblastoma imaging is the somatostatin receptor (sstr) that is present in many neuroendocrine tumours (net). the superior pet imaging technology used with new radiotracers (such as 68ga-dotatate) enables imaging at advantageous resolutions well below what is possible by current clinical spect systems that are used for 123i-mibg. design: prospective single-arm non-randomized clinical trial (phase ii) - pilot objective: 1) assess the feasibility and safety of 68ga-dotatate pet/ct imaging in patients with neuroblastoma or suspected of having neuroblastoma. 2) compare lesion-by-lesion the uptake of 68ga-dotatate and 123i-mibg in the same participant. study population: children and adults with biopsy-proven or suspected neuroblastoma procedure and follow-up: few days after 123i-mibg scan, participants will undergo a 68ga-dota-ctate pet/ct scan (duration 2 hours). clinical data will be collected from this imaging and from the participant's medical record (demographic, treatment, medication, pathology, lab test results) for a 2-year follow-up period.

Eligibility criteria:
inclusion criteria: * newly suspected or biopsy-proven neuroblastoma or recurrence of neuroblastoma * planned 123i-mibg imaging * able and willing to provide signed informed consent in french or english (for the adult candidates or the parent/legal tutor of the pediatric candidates) * aged between 1 day and 21 years old (inclusively). exclusion criteria: * history of another cancer in the past 5 years other than non-melanomatous skin cancer. * currently under a randomized control trial with unknown allocation; * currently under treatment; * medical/surgical intervention on the tumour between 123i-mibg and 68ga-dotatate pet/ct scan. * medically unstable or unable to undergo scan. * pregnancy (breastfeeding is not an exclusion criterion but needs to be stopped for at least 12 hours after 68ga-dotatate injection). * prior allergic reaction to somatostatin analogues

Keywords: imaging 68ga-dotatate 68ga-octreotate positron emission tomography (pet)
phase iv study: vunakizumab efficacy and safety in moderate-to-severe plaque psoriasis

Conditions: Moderate to Severe Plaque Psoriasis

Summary: this is a multicenter, prospective, observational study of 1516 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of vunakizumab in patients with moderate-to-severe chronic plaque psoriasis. approximately 50-100 clinical trial centers are planned to participate in the study. the study consisted of a 7-day screening period, a 52-week treatment period and an 8-week safety follow-up period. the recommended dose of vunakizumab is 240 mg (120 mg in two injections), with subcutaneous injection at week 0, 2, and 4, followed by a dose every 4 weeks and a final injection at week 48 (the actual treatment regimen is based on the clinician's recommendation). after the corresponding assessment at 52 weeks, an 8-week safety follow-up period was entered until the end of the study.

the vunakizumab is a humanized il-17a inhibitor with innovative binding epitopes, which accurately binds to il-17a, the core pathogenic factor of psoriasis. however, there is still a lack of efficacy and safety data in a large sample size of the chinese population after marketing. therefore, this study is intended to observe the efficacy and safety of vunachizumab in a larger population. the clinical efficacy of vunakizumab on special sites and the influence of comorbidity on the treatment of psoriasis are also paid attention to. at the same time, the improvement effect of vunakizumab on the quality of life and mental health of psoriasis patients is explored through patient-reported outcome (pro) and patient satisfaction survey, so as to develop a clinical program that can benefit psoriasis patients physically and mentally.

Eligibility criteria:
inclusion criteria: * age ≥18 years old at the time of signing the informed consent, regardless of gender; * moderate to severe plaque psoriasis was diagnosed; * plan to receive vunakizumab therapy as assessed by the investigator; * the subject voluntarily signs informed consent before the start of any procedures related to the study, can communicate with the researcher smoothly, understands and is willing to strictly comply with the requirements of this clinical study protocol to complete the study; patients voluntarily sign informed consent forms. exclusion criteria: * previous treatment with biological agents: including but not limited to anti-tumor necrosis factor-α (tnf-α), anti-il-17, anti-il-17 receptor, anti-il-12 /il-23 or il-23p19 antibody drugs; * severe hypersensitivity to vunakizumab active ingredient or any excipients; * patients with clinically important active diseases, such as active tuberculosis, active hepatitis, and active malignant tumors; * fertile women (defined as all women with physical conditions necessary for pregnancy) and men who are pregnant or unwilling or unable to use highly effective birth control during the study period and within 20 weeks after last receiving the study drug; * any other circumstances that the investigator believes will prevent the subject from following and completing the study protocol.
clinical study of umbilical cord mesenchymal stem cells combined with collagen scaffold in the treatment of thin endometrium

Conditions: Thin Endometrium; Intrauterine Adhesion

Summary: this is a non-blind self-control trial. we mainly compare the changes of endometrial thickness，changes in menstrual flow, and improvement in pregnancy before and after stem cell treatment in patients with thin endometrium.

according to the medical history and the results of the examination, the selected cases were screened and the informed consent was signed. after hysteroscopy, the collagen/umbilical cord mesenchymal stem cell was spread on a foley catheter, and placed in the uterine cavity, and 5 ml of saline was filled into the balloon. b-ultrasound confirmed that the stent was attached to the uterine wall. the balloon was removed in situ after 1 week. we mainly compare the endometrial thickness before and 6 months after surgery.

Eligibility criteria:
inclusion criteria: 1. according to the gcp regulations, obtain the informed consent of the subject, volunteer for the test, and have signed the informed consent form. 2. women aged 20-40 years with fertility requirements 3. infertility patients who are treated in this hospital 4. after more than 2 times of hysteroscopic adhesion separation surgery, the uterine cavity morphology has basically returned to normal. the patient has a normal menstrual cycle or an estrogenic dose of 6 mg per day, and the highest thickness of the endometrium is 5.5 mm in 6 cycles by ultrasound. 5. or receive adjuvant reproductive treatment, the endometrial thickness is less than 5.5mm for unknown reasons, the treatment of estrogen, colony stimulating factor, aspirin, sildenafil and other drugs up to 8mg / day is invalid. 6. hbvag negative, hcv negative, hiv negative, syphilis negative 7. normal bone marrow morphology, normal blood routine 8. previously failed to receive relevant stem cell therapy exclusion criteria: 1. those who cannot accept the treatment observation process required by the test 2. there are contraindications for hysteroscopic surgery; 3. congenital uterine malformation; severe adenomyosis; uterine fibroids that may affect embryo implantation; the investigators judged that there are other uterine factors that are not suitable for embryo implantation 4. patients with chromosomal abnormalities 5. contraindications to estrogen therapy; systemic diseases such as thrombosis, cardiopulmonary disease, hematopoietic diseases, malignant tumors, etc. 6. patients without fertility requirements

Keywords: thin endometrium intrauterine adhesion stem cell collagen scaffold
modulating early-life nutrition for childhood obesity prevention

Conditions: Infant Growth; Childhood Overweight

Summary: in this study, betaine intake will be increased in formula-fed infants through formula milk supplementation. to do this, a double-blind randomized study has been designed with the supplementation group (infant formula supplemented with betaine) and control group (unsupplemented infant formula). the main objectives of the study are to determine the safety of supplementation and to assess whether there are changes in infant growth.

childhood obesity is one of the main public health concerns worldwide. previous results have linked a nutrient called betaine (trimethylglycine) to the risk of childhood obesity. betaine is a modified amino acid with osmotic properties that participates in the methionine cycle as a methyl group donor. specifically, previous data demonstrate a link between breast milk betaine content, postnatal growth, and long-term metabolic health, suggesting that betaine supplementation may be an effective strategy for regulating growth trajectories and preventing childhood obesity. this study will assess the effects of increasing betaine intake in formula-fed infants through formula milk supplementation. to do this, a double-blind randomized study has been designed where participants will be randomly assigned to the control group or the supplementation group. the main objectives of the study are to determine the safety of supplementation and to assess whether there are changes in infant growth. additionally, potential changes in the intestinal microbiome induced by the increase in betaine intake will be analyzed.

Eligibility criteria:
inclusion criteria: * maternal age between 17 and 42 years * maternal pre-pregnancy bmi equal or higher than 25 * gestational age at birth \> 37 weeks * no exclusive breastfeeding at time of recruitment exclusion criteria: * presence of disease or malformations in the infant * infant birth weight \< -1 sd (standard deviations) * multiple pregnancy * elective c-section

Keywords: betaine infant formula childhood obesity risk infant growth one-carbon metabolism
curcumin biomarkers

Conditions: Colorectal Cancer

Summary: colorectal cancer is a major problem in the united states and other developed countries. a safe and effective chemopreventive agent could reduce the burden of colorectal neoplasia. curcumin, is a product that is derived from curcuma longa. it has been used for thousands of years as a traditional remedy. curcumin blocks a number of targets involved in tumor initiation, promotion, and progression, and is considered a promising chemopreventive agent. the investigators propose to enroll 40 patients after screening colonoscopy who will have rectal biopsies at baseline and after 4 weeks of curcumin 4 grams per day. the investigators will use microarray analysis to identify genes that are modified by curcumin that could be used as biomarkers in future chemoprevention studies. the study will also evaluate tolerability and toxicity.


Eligibility criteria:
inclusion criteria: 1. age 40 - 80. 2. a willingness to follow the study protocol, as indicated by provision of informed consent to participate 3. good general health exclusion criteria: 1. familial colorectal cancer syndromes (e.g. hereditary non-polyposis colon cancer, familial adenomatous polyposis) 2. ulcerative colitis or crohn's disease. 3. history of large bowel resection for any reason 4. diagnosed narcotic or alcohol dependence 5. unwillingness to forgo curcumin/turmeric-containing supplements during the trial or consumption of curry/turmeric at meals \> 3 times a week. 6. allergy to turmeric/curcumin. 7. women with childbearing potential who do not agree to practice effective birth control. 8. individuals with creatinine, ast or alt above 1.5 times the upper limit of normal at baseline. 9. personal or inherited bleeding disorders or therapeutic anti-coagulation with warfarin. 10. women who are pregnant or nursing. 11. individuals who have taken antibiotics within the three months prior to enrollment.

Keywords: curcumin colorectal cancer gwas
a phase ii study of pioglitazone for patients with cancer of the pancreas

Conditions: Cancer of the Pancreas

Summary: this study is being done to determine whether or not addition of the oral medication, pioglitazone to standard chemotherapy, results in improvement of blood tests that measure the body's ability to utilize sugar (glucose and insulin metabolism). in addition the investigators want to determine whether or not treatment with pioglitazone results in (1) improvement in the size of the tumor, (2) weight gain, (3) improved ability to function during the day and (4) quality of life.


Eligibility criteria:
inclusion criteria: * signed informed consent * histologically proven adenocarcinoma of the pancreas * radiologically measurable disease * ecog functional status 0-2 exclusion criteria: * prior radiation therapy for pancreatic cancer if chemotherapy is planned, new chemotherapy regimen should have started more than 14 days prior to enrollment * surgery or radiation planned within 8 weeks of starting therapy * prior exposure to thiazolidinedione (tzd) therapy in the past 12 months * hypersensitivity of tzd * new york heart association class iii/iv heart failure. * known hiv positive * pregnant or lactating women * history of, or active bladder cancer * inadequate hepatic function documented within 14 days of enrollment * total bilirubin level \> 1.5 x uln * ast and alt \> 2.5 x uln, unless there are liver metastases in which case ast and alt or \> 5 x uln
physical activity following the containment period imposed by the covid-19 pandemic in patients

Conditions: Physical Activity; COVID-19

Summary: in the context of the containment imposed by the covid-19 pandemic and taking into account the numerous restrictions imposed, the practice of physical and sports activities (psa) could be reduced by general population and sports population. while the practice of regular physical activity (pa) is prescribed and widely recognized as effective for the management of many chronic conditions and that regular participation in sports (sa) reduces the risk of injury and cardiac accidents- vascular disease in sports subjects, the reduction in regular physical activity levels in the wake of the period of confinement is likely to induce a medical risk in connection with the resumption of psa.

the study is non-interventional. the data that will be collected are data that can be integrated into a care procedure in accordance with the recommendations to accompany the patients with chronic pathology and athletes for the resumption of psa after hypothetical deconditioning. support will be implemented in accordance with the recommendations of the hcsp and the ministry of sports. the objective of this study is to evaluate the data of this recommended medical follow-up. the questionnaires used for the subjects' self-evaluation are all validated in french language, used in the context of medical monitoring, and used in clinical research: assessment of physical activity levels by the questionnaire of ricci and gagnon (rg), evaluation of the level of anxiety and depression by the hospital and anxiety scale depression (ahh), assessment of sleep quality by the score of leeds. medical questionnaires to assess the evolutionary stage of chronic pathologies (ms, parkinson's disease and fibromyalgia) will be informed by the investigating physician during the interview telephone with the patient.

Eligibility criteria:
inclusion criteria: * non-working or tele-working subjects, subjects who have returned to work, subjects who have taken up a part-time professional activity, subjects who have resumed an activity full-time professional * subjects who have given their consent * for the sports topics group: amateur level (no sportsmen and women professionals), including sports subjects in the disabled category, with no chronic pathology, already followed by the investigating medical units. * for the group of patients with chronic diseases: subjects carrying a chronic pathology (rheumatic pathologies, etc) and fibromyalgia, parkinson's disease and multiple sclerosis, cancer of the breast, metabolic diseases without cardiovascular failure) usually accompanied by the medical units for the implementation of a programme of physic adapted and medically prescribed (sport-santé approach) * social security affiliation exclusion criteria: * patient under the protection of adults (guardianship, curators), safeguard of justice), * pregnant and/or breastfeeding woman.

Keywords: anxiety sleep chronic pathology
beijing disability risk and ageing monitoring study

Conditions: Age Problem; Disability; Death

Summary: this is a community-based prospective cohort study in beijing, china. the study has been initialized in 2023 and enrolled older residents. this study aims to develop disability risk assessment standards and an early warning model for older adults.

this is a community-based prospective cohort study. individuals who aged 60 years or older, lived in the communities for more than 1 year, and signed the informed consent form were enrolled in the present study. the study has been initialized in 2023 and aimed to develop an early warning model and a series of disability risk assessment methods for older adults. this work consists of three steps as following. first, we will build a community-based cohort and thus set up a database. second, an intelligence model for disability risk assessment will be developed using the database. third, a series of procedures will be established according to the risk assessment model.

Eligibility criteria:
inclusion criteria: * aged 60 years or older * lived in the community for more than 1 year * signed the informed consent form exclusion criteria: * cannot complete the survey

Keywords: disability, ageing, cohort
infections after renal transplantation: diseases pattern in hong kong

Conditions: Kidney Transplantation; Infection

Summary: infections are the most feared complications developing in patient who had had kidney transplantation. the aim of this study is to document the local disease pattern among this group of patients.


Eligibility criteria:
inclusion criteria: * all living-related or cadaveric renal transplantation episodes (including preemptive ones) performed in the hong kong special administration region (hksar), mainland china or overseas during the period 1/1/2000 to 30/6/2005 exclusion criteria: * multiple organ recipients, incomplete records and lost to follow-up, including those cases who have been taken over by other renal centres

Keywords: infections